4//SEC Filing
Dankner Nochi 4
Accession 0001178913-12-000620
CIK 0001451980other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 2:13 PM ET
Size
25.9 KB
Accession
0001178913-12-000620
Insider Transaction Report
Form 4
Clal Biotechnology Industries Ltd.
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
IDB HOLDING CORP LTD
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
CLAL INDUSTRIES & INVESTMENTS LTD
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
IDB DEVELOPMENT CORP LTD
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
Manor Ruth
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
Livnat Avraham
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
Dankner Nochi
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
Bergman Shelly
10% Owner
Transactions
- Purchase
Common stock
2012-01-24$0.26/sh+8,199,400$2,131,844→ 12,444,237 total - Other
Common stock
2012-01-24+410,392→ 12,444,237 total
Footnotes (2)
- [F1]As more particularly described in the Statement on Schedule 13D (the "Schedule 13D") filed by Clal Biotechnology Industries Ltd. and the other reporting persons identified therein with the United States Securities and Exchange Commission on the date hereof, the 8,199,400 shares of Common Stock reported acquired herein were acquired through a private placement that was executed in New Israeli Shekel ("NIS") at a price of NIS 1.00 per share. The price indicated in the table is based on the exchange rate of NIS and US dollar reported by the Bank of Israel on March 6, 2012 (NIS 3.814 for US$1.00).
- [F2]As more particularly described in the Schedule 13D, as a result of the transaction (see footnote 1 above), the 410,392 shares of Common Stock were issued for no consideration pursuant to contractual anti-dilution undertakings of the Issuer in its Subscription and Registration Rights Agreement with Clal Biotechnology Industries Ltd., dated June 22, 2008.
Documents
Issuer
BIOCANCELL THERAPEUTICS INC.
CIK 0001451980
Entity typeother
Related Parties
1- filerCIK 0001355204
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 2:13 PM ET
- Size
- 25.9 KB